{"id":"NCT01496274","sponsor":"CSL Behring","briefTitle":"A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","officialTitle":"A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-02","primaryCompletion":"2014-07","completion":null,"firstPosted":"2011-12-21","resultsPosted":"2016-05-09","lastUpdate":"2016-05-09"},"enrollment":63,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia B"],"interventions":[{"type":"BIOLOGICAL","name":"rIX-FP","otherNames":[]}],"arms":[{"label":"Prophylaxis","type":"EXPERIMENTAL"},{"label":"On-demand","type":"EXPERIMENTAL"}],"summary":"This study will examine the safety, pharmacokinetics and efficacy of rIX-FP for the control and prevention of bleeding episodes in subjects who have previously received factor replacement therapy for hemophilia B.","primaryOutcome":{"measure":"Change in Frequency of Spontaneous Bleeding Events Between On-demand and Prophylaxis Treatments (Annualized)","timeFrame":"Up to 26 weeks for on-demand regimen, and between 1 and 17 months for prophylaxis regimen.","effectByArm":[{"arm":"On-demand Arm, On-demand Regimen","deltaMin":15.43,"sd":null},{"arm":"On-demand Arm, Prophylaxis Regimen","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":30,"countries":["United States","Austria","Bulgaria","France","Germany","Israel","Italy","Japan","Russia","Spain"]},"refs":{"pmids":["26755710"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":40},"commonTop":["NASOPHARYNGITIS","HEADACHE","ARTHRALGIA","INFLUENZA","LIMB INJURY"]}}